 |
Journal articles
Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients
Simon Funnell
1, *
William Dowling
2
César Muñoz-Fontela
3
Pierre-Stéphane Gsell
4
Donald Ingber
5
Geraldine Hamilton
6
Leen Delang
7
Joana Rocha-Pereira
7
Suzanne Kaptein
7
Kai Dallmeier
7
Johan Neyts
7
Kyle Rosenke
8
Emmie de Wit
8
Heinz Feldmann
8
Pauline Maisonnasse
9
Roger Le Grand
9
Matthew Frieman
10
Christopher Coleman
11
*
Corresponding author
Simon G P Funnell 1
Correspondent author
William E Dowling 2
Author
César Muñoz-Fontela 3
Author
Pierre-Stéphane Gsell 4
Author
Donald E Ingber 5
Author
Geraldine A Hamilton 6
Author
Leen Delang 7
Author
Joana Rocha-Pereira 7
Author
Matthew B Frieman 10
Author
Christopher M Coleman 11
Author
1
Public Health England [London] (Wellington House , 133-155 Waterloo Road, London SE1 8UG - United Kingdom)
2
CEPI - Coalition for Epidemic Preparedness Innovations [Washington, DC, États-Unis] (United States)
3
BNITM - Bernhard Nocht Institute for Tropical Medicine - Bernhard-Nocht-Institut für Tropenmedizin [Hamburg, Germany] (Bernhard-Nocht-Straße 74, 20359 Hamburg. - Germany)
4
OMS / WHO - Organisation Mondiale de la Santé / World Health Organization Office (Genève - Switzerland)
5
Harvard University [Cambridge] (Massachusetts Hall, Cambridge, MA 02138 - United States)
6
Emulate, Inc. [Boston, MA, États-Unis] (United States)
7
KU Leuven - Catholic University of Leuven - Katholieke Universiteit Leuven (Oude Markt 13 - bus 5005, 3000 Leuven - Belgium)
8
National Institute of Health [Hamilton, MT, États-Unis] (United States)
9
IMVA-HB - Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (18 route du Panorama, 92265, Fontenay-aux-Roses cedex - France)
- CEA - Commissariat à l'énergie atomique et aux énergies alternatives (Centre de Saclay Centre de Grenoble Centre de Cadarache etc - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U 1184 (101, rue de Tolbiac, 75013 Paris - France)
- Université Paris-Saclay (Espace Technologique, Bat. Discovery - RD 128 - 2e ét., 91190 Saint-Aubin - France)
10
University of Maryland School of Medicine (655 W. Baltimore Street, Baltimore MD 21201 - United States)
- University of Maryland System (United States)
11
UON - University of Nottingham, UK (University of Nottingham
University Park
Nottingham
NG7 2RD - United Kingdom)
Abstract : There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collaborative effort of independent researchers who have recently all come to the same conclusion—that chloroquine or hydroxchloroquine are unlikely to provide clinical benefit against COVID-19.
Document type :
Journal articles
Complete list of metadata
https://www.hal.inserm.fr/inserm-02964247
Contributor : Myriam Bodescot <>
Submitted on : Monday, October 12, 2020 - 11:57:17 AM
Last modification on : Monday, March 29, 2021 - 2:44:20 PM
Long-term archiving on: : Wednesday, January 13, 2021 - 6:42:08 PM
Contributor : Myriam Bodescot <>
Submitted on : Monday, October 12, 2020 - 11:57:17 AM
Last modification on : Monday, March 29, 2021 - 2:44:20 PM
Long-term archiving on: : Wednesday, January 13, 2021 - 6:42:08 PM
File
s41467-020-17907-w.pdf
Publication funded by an institution
Identifiers
- HAL Id : inserm-02964247, version 1
- DOI : 10.1038/s41467-020-17907-w
- PUBMED : 32848158
- PUBMEDCENTRAL : PMC7450055
Citation
Simon Funnell, William Dowling, César Muñoz-Fontela, Pierre-Stéphane Gsell, Donald Ingber, et al.. Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.4253. ⟨10.1038/s41467-020-17907-w⟩. ⟨inserm-02964247⟩
Metrics
Record views
73
Files downloads